ARCHIVES

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

This article is from The Cancer Letter archive.

Vol. 11 No. 14 | April 5, 1985

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

Fadlo Khuri Named Editor-in-Chief Of ACS Journal Cancer

August 12, 2011

Parkinson Heads Oncology At Amgen

May 2, 2003

Doctor-Patient Interaction May Cause Racial Disparity

February 24, 2006

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

House Measure Would Eliminate AHRQ, Rescind PCORI, Cut Outcomes Research, And Halt NIH’s Title 42 Hiring Program

July 20, 2012